Technical Choices in Pediatric Living Donor Liver Transplantation: The Path to Reduce Vascular Complications and Improve Survival

João Seda Neto, Eduardo A. Fonseca, Rodrigo Vincenzi, Renata Pugliese, Marcel R. Benavides, Karina Roda, Gilda Porta, Irene K. Miura, Adriana Porta, Christian Borges, Vera Baggio, Flavia H. Feier, Hsiang Teng, Mônica L. Rodrigues, Fernanda C. Iwase, Mário Kondo, Paulo Chapchap – 27 August 2020 – Pediatric living donor liver transplantation (PLDLT) is a successful therapeutic option for children with chronic and acute liver disease. After early transplant results, many technical advancements were introduced in the field to reduce the rate of complications and improve survival.

Genome‐wide Association Study and Meta‐analysis on Alcohol‐Associated Liver Cirrhosis Identifies Genetic Risk Factors

Tae‐Hwi Schwantes‐An, Rebecca Darlay, Philippe Mathurin, Steven Masson, Suthat Liangpunsakul, Sebastian Mueller, Guruprasad P. Aithal, Florian Eyer, Dermot Gleeson, Andrew Thompson, Beat Muellhaupt, Felix Stickel, Michael Soyka, David Goldman, Tiebing Liang, Lawrence Lumeng, Munir Pirmohamed, Bertrand Nalpas, Jean‐Marc Jacquet, Romain Moirand, Pierre Nahon, Sylvie Naveau, Pascal Perney, Greg Botwin, Paul S. Haber, Helmut K. Seitz, Christopher P. Day, Tatiana M. Foroud, Ann K. Daly, Heather J. Cordell, John B. Whitfield, Timothy R.

Antibody Response to Severe Acute Respiratory Syndrome‐ Corona Virus 2, Diagnostic and Therapeutic Implications

Yuval Ishay, Asa Kessler, Asaf Schwarts, Yaron Ilan – 26 August 2020 – The immune response against severe acute respiratory syndrome‐corona virus 2 (SARS‐CoV‐2) is comprised of both cellular and humoral arms. While current diagnostic methods are mainly based on polymerase chain reaction, they suffer from insensitivity. Therefore, antibody‐based serologic tests are being developed to achieve higher sensitivity and specificity.

Extracellular Vesicles as a Novel Therapeutic Option in Liver Transplantation

Kristin Carlson, John Kink, Peiman Hematti, David P. Al‐Adra – 25 August 2020 – Longterm liver graft dysfunction and immunological rejection remain common adverse events, in part due to early acute rejection episodes initiated by ischemia/reperfusion injury (IRI) immediately following transplantation. Novel treatment methods are therefore required to ameliorate liver IRI and to promote longterm allograft acceptance.

Subscribe to